Autres langues Orion Oyj

Actions

ORNBV

FI0009014377

Produits pharmaceutiques

Marché Fermé - Nasdaq Helsinki 18:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
81,50 ^EUR	-0,18%		+3,95%	+28,04%

17/09	Sources : Orion180 fixerait son prix d'introduction en dessous de la fourchette initiale - BN (R)	FW
17/09	Sources : Orion180 fixerait son prix d'introduction en dessous de la fourchette initiale - BN	FW

Autres langues

18/09	Orion Corporation: Acquisition of own shares during week 38, 2026
11/09	Orion Corporation: Acquisition of own shares during week 37, 2026
04/09	Orion Corporation: Acquisition of own shares during week 36, 2026
04/09	102,000 Orion Corporation A shares converted into B shares
04/09	Orion Oyj commences an Equity Buyback Plan for 500,000 shares, representing 0.46% of its issued share capital, under the authorization approved on March 24, 2026.
27/08	Orion Corporation to commence acquisition of own shares for its share-based incentive plans
10/08	Orion License Partner Tenax's Pulmonary Hypertension Drug Fails to Improve Walk Distance in Late-stage Trial
10/08	Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
17/07	Orion Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
17/07	Orion Oyj Revises Earnings Guidance for the Full Year 2026
17/07	Orion Oyj : Half-Year Financial Report 2026
17/07	Orion Group Half-Year Financial Report January–June 2026
17/07	Orion Corporation’s financial reporting and Annual General Meeting in 2027
15/07	45,611 Orion Corporation A shares converted into B shares
06/07	Shilpa Biologicals Private Limited and Orion Corporation Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe
06/07	Orion publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026
03/07	Orion Oyj : publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026
03/07	Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026
30/06	Tenax Therapeutics, Inc. and Orion Corporation Enter Supply Agreement For Manufacture and Supply of Orally Administered Levosimendan Product
30/06	Orion Pharma and Shilpa Biologicals Private Limited Enter Agreement for Distribution and Marketing of Nivolumab Biosimilar in Europe
30/06	Orion Signs Marketing Deal for Shilpa Medicare's Cancer Therapy Biosimilar in Europe
30/06	Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
23/06	Orion's Investigational Drug Wins EU Orphan Drug Designation to Treat Malignant Mesothelioma
23/06	Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
18/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)